schliessen

Filtern

 

Bibliotheken

In vitro anti-Leishmania activity of tetracyclic iridoids from Morinda lucida, benth

Leishmaniasis is an infectious disease transmitted by the sand fly. It is caused by over 20 different species of Leishmania and has affected over 14 million people worldwide. One of the main forms of control of leishmaniasis is chemotherapy, but this is limited by the high cost and/or toxicity of av... Full description

Journal Title: Tropical medicine and health 2016, Vol.44, pp.25
Main Author: Amoa-Bosompem, Michael
Other Authors: Ohashi, Mitsuko , Mosore, Mba-Tihssommah , Agyapong, Jeffrey , Tung, Nguyen Huu , Kwofie, Kofi D , Ayertey, Frederick , Owusu, Kofi Baffuor-Awuah , Tuffour, Isaac , Atchoglo, Philip , Djameh, Georgina I , Azerigyik, Faustus A , Botchie, Senyo K , Anyan, William K , Appiah-Opong, Regina , Uto, Takuhiro , Morinaga, Osamu , Appiah, Alfred A , Ayi, Irene , Shoyama, Yukihiro , Boakye, Daniel A , Ohta, Nobuo
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 1348-8945 ; PMID: 27536194 Version:1 ; DOI: 10.1186/s41182-016-0026-5
Link: http://pubmed.gov/27536194
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline27536194
title: In vitro anti-Leishmania activity of tetracyclic iridoids from Morinda lucida, benth
format: Article
creator:
  • Amoa-Bosompem, Michael
  • Ohashi, Mitsuko
  • Mosore, Mba-Tihssommah
  • Agyapong, Jeffrey
  • Tung, Nguyen Huu
  • Kwofie, Kofi D
  • Ayertey, Frederick
  • Owusu, Kofi Baffuor-Awuah
  • Tuffour, Isaac
  • Atchoglo, Philip
  • Djameh, Georgina I
  • Azerigyik, Faustus A
  • Botchie, Senyo K
  • Anyan, William K
  • Appiah-Opong, Regina
  • Uto, Takuhiro
  • Morinaga, Osamu
  • Appiah, Alfred A
  • Ayi, Irene
  • Shoyama, Yukihiro
  • Boakye, Daniel A
  • Ohta, Nobuo
subjects:
  • Chemotherapy
  • Cytokinesis
  • Leishmania
  • Leishmaniasis
  • Microscopy
  • Morphology
  • Proliferation
ispartof: Tropical medicine and health, 2016, Vol.44, pp.25
description: Leishmaniasis is an infectious disease transmitted by the sand fly. It is caused by over 20 different species of Leishmania and has affected over 14 million people worldwide. One of the main forms of control of leishmaniasis is chemotherapy, but this is limited by the high cost and/or toxicity of available drugs. We previously found three novel compounds with an iridoid tetracyclic skeleton to have activity against trypanosome parasites. In this study, we determined the activity of the three anti-trypanosome compounds against Leishmania using field strain, 010, and the lab strain Leishmania hertigi. The minimum inhibitory concentration (MIC) of the compounds against 010 was determined by microscopy while the IC50 of compounds against L. hertigi was determined by fluorescence-activated cell sorting with Guava viacount analysis. We found two of the three compounds, molucidin and ML-F52, to have anti-Leishmania activity against both strains. The fluor-microscope observation with DAPI stain revealed that both Molucidin and ML-F52 induced abnormal parasites with two sets of nucleus and kinetoplast in a cell, suggesting that compounds might inhibit cytokinesis in Leishmania parasites. Molucidin and ML-F52 might be good lead compounds for the development of new anti-Leishmania chemotherapy.
language: eng
source:
identifier: ISSN: 1348-8945 ; PMID: 27536194 Version:1 ; DOI: 10.1186/s41182-016-0026-5
fulltext: fulltext
issn:
  • 13488945
  • 1348-8945
url: Link


@attributes
ID284621414
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid27536194
sourceidmedline
recordidTN_medline27536194
sourceformatXML
sourcesystemOther
pqid1812890023
display
typearticle
titleIn vitro anti-Leishmania activity of tetracyclic iridoids from Morinda lucida, benth
creatorAmoa-Bosompem, Michael ; Ohashi, Mitsuko ; Mosore, Mba-Tihssommah ; Agyapong, Jeffrey ; Tung, Nguyen Huu ; Kwofie, Kofi D ; Ayertey, Frederick ; Owusu, Kofi Baffuor-Awuah ; Tuffour, Isaac ; Atchoglo, Philip ; Djameh, Georgina I ; Azerigyik, Faustus A ; Botchie, Senyo K ; Anyan, William K ; Appiah-Opong, Regina ; Uto, Takuhiro ; Morinaga, Osamu ; Appiah, Alfred A ; Ayi, Irene ; Shoyama, Yukihiro ; Boakye, Daniel A ; Ohta, Nobuo
ispartofTropical medicine and health, 2016, Vol.44, pp.25
identifier
subjectChemotherapy ; Cytokinesis ; Leishmania ; Leishmaniasis ; Microscopy ; Morphology ; Proliferation
descriptionLeishmaniasis is an infectious disease transmitted by the sand fly. It is caused by over 20 different species of Leishmania and has affected over 14 million people worldwide. One of the main forms of control of leishmaniasis is chemotherapy, but this is limited by the high cost and/or toxicity of available drugs. We previously found three novel compounds with an iridoid tetracyclic skeleton to have activity against trypanosome parasites. In this study, we determined the activity of the three anti-trypanosome compounds against Leishmania using field strain, 010, and the lab strain Leishmania hertigi. The minimum inhibitory concentration (MIC) of the compounds against 010 was determined by microscopy while the IC50 of compounds against L. hertigi was determined by fluorescence-activated cell sorting with Guava viacount analysis. We found two of the three compounds, molucidin and ML-F52, to have anti-Leishmania activity against both strains. The fluor-microscope observation with DAPI stain revealed that both Molucidin and ML-F52 induced abnormal parasites with two sets of nucleus and kinetoplast in a cell, suggesting that compounds might inhibit cytokinesis in Leishmania parasites. Molucidin and ML-F52 might be good lead compounds for the development of new anti-Leishmania chemotherapy.
languageeng
source
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/27536194$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Amoa-Bosompem, Michael
1Ohashi, Mitsuko
2Mosore, Mba-Tihssommah
3Agyapong, Jeffrey
4Tung, Nguyen Huu
5Kwofie, Kofi D
6Ayertey, Frederick
7Owusu, Kofi Baffuor-Awuah
8Tuffour, Isaac
9Atchoglo, Philip
10Djameh, Georgina I
11Azerigyik, Faustus A
12Botchie, Senyo K
13Anyan, William K
14Appiah-Opong, Regina
15Uto, Takuhiro
16Morinaga, Osamu
17Appiah, Alfred A
18Ayi, Irene
19Shoyama, Yukihiro
20Boakye, Daniel A
21Ohta, Nobuo
titleIn vitro anti-Leishmania activity of tetracyclic iridoids from Morinda lucida, benth
descriptionLeishmaniasis is an infectious disease transmitted by the sand fly. It is caused by over 20 different species of Leishmania and has affected over 14 million people worldwide. One of the main forms of control of leishmaniasis is chemotherapy, but this is limited by the high cost and/or toxicity of available drugs. We previously found three novel compounds with an iridoid tetracyclic skeleton to have activity against trypanosome parasites. In this study, we determined the activity of the three anti-trypanosome compounds against Leishmania using field strain, 010, and the lab strain Leishmania hertigi. The minimum inhibitory concentration (MIC) of the compounds against 010 was determined by microscopy while the IC50 of compounds against L. hertigi was determined by fluorescence-activated cell sorting with Guava viacount analysis. We found two of the three compounds, molucidin and ML-F52, to have anti-Leishmania activity against both strains. The fluor-microscope observation with DAPI stain revealed that both Molucidin and ML-F52 induced abnormal parasites with two sets of nucleus and kinetoplast in a cell, suggesting that compounds might inhibit cytokinesis in Leishmania parasites. Molucidin and ML-F52 might be good lead compounds for the development of new anti-Leishmania chemotherapy.
subject
0Chemotherapy
1Cytokinesis
2Leishmania
3Leishmaniasis
4Microscopy
5Morphology
6Proliferation
general
027536194
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
310.1186/s41182-016-0026-5
4MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline27536194
issn
013488945
11348-8945
rsrctypearticle
creationdate2016
addtitleTropical medicine and health
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr412016
citationpf 25 vol 44
startdate20160101
enddate20161231
lsr30VSR-Enriched:[issue, eissn, pqid]
sort
titleIn vitro anti-Leishmania activity of tetracyclic iridoids from Morinda lucida, benth
authorAmoa-Bosompem, Michael ; Ohashi, Mitsuko ; Mosore, Mba-Tihssommah ; Agyapong, Jeffrey ; Tung, Nguyen Huu ; Kwofie, Kofi D ; Ayertey, Frederick ; Owusu, Kofi Baffuor-Awuah ; Tuffour, Isaac ; Atchoglo, Philip ; Djameh, Georgina I ; Azerigyik, Faustus A ; Botchie, Senyo K ; Anyan, William K ; Appiah-Opong, Regina ; Uto, Takuhiro ; Morinaga, Osamu ; Appiah, Alfred A ; Ayi, Irene ; Shoyama, Yukihiro ; Boakye, Daniel A ; Ohta, Nobuo
creationdate20160000
lso0120160000
facets
frbrgroupid8349379412139892301
frbrtype5
newrecords20190701
languageeng
creationdate2016
topic
0Chemotherapy
1Cytokinesis
2Leishmania
3Leishmaniasis
4Microscopy
5Morphology
6Proliferation
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Amoa-Bosompem, Michael
1Ohashi, Mitsuko
2Mosore, Mba-Tihssommah
3Agyapong, Jeffrey
4Tung, Nguyen Huu
5Kwofie, Kofi D
6Ayertey, Frederick
7Owusu, Kofi Baffuor-Awuah
8Tuffour, Isaac
9Atchoglo, Philip
10Djameh, Georgina I
11Azerigyik, Faustus A
12Botchie, Senyo K
13Anyan, William K
14Appiah-Opong, Regina
15Uto, Takuhiro
16Morinaga, Osamu
17Appiah, Alfred A
18Ayi, Irene
19Shoyama, Yukihiro
20Boakye, Daniel A
21Ohta, Nobuo
jtitleTropical Medicine And Health
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Amoa-Bosompem
1Ohashi
2Mosore
3Agyapong
4Tung
5Kwofie
6Ayertey
7Owusu
8Tuffour
9Atchoglo
10Djameh
11Azerigyik
12Botchie
13Anyan
14Appiah-Opong
15Uto
16Morinaga
17Appiah
18Ayi
19Shoyama
20Boakye
21Ohta
aufirst
0Michael
1Mitsuko
2Mba-Tihssommah
3Jeffrey
4Nguyen Huu
5Kofi D
6Frederick
7Kofi Baffuor-Awuah
8Isaac
9Philip
10Georgina I
11Faustus A
12Senyo K
13William K
14Regina
15Takuhiro
16Osamu
17Alfred A
18Irene
19Yukihiro
20Daniel A
21Nobuo
au
0Amoa-Bosompem, Michael
1Ohashi, Mitsuko
2Mosore, Mba-Tihssommah
3Agyapong, Jeffrey
4Tung, Nguyen Huu
5Kwofie, Kofi D
6Ayertey, Frederick
7Owusu, Kofi Baffuor-Awuah
8Tuffour, Isaac
9Atchoglo, Philip
10Djameh, Georgina I
11Azerigyik, Faustus A
12Botchie, Senyo K
13Anyan, William K
14Appiah-Opong, Regina
15Uto, Takuhiro
16Morinaga, Osamu
17Appiah, Alfred A
18Ayi, Irene
19Shoyama, Yukihiro
20Boakye, Daniel A
21Ohta, Nobuo
atitleIn vitro anti-Leishmania activity of tetracyclic iridoids from Morinda lucida, benth
jtitleTropical medicine and health
date2016
risdate2016
volume44
spage25
pages25
issn1348-8945
formatjournal
genrearticle
ristypeJOUR
abstractLeishmaniasis is an infectious disease transmitted by the sand fly. It is caused by over 20 different species of Leishmania and has affected over 14 million people worldwide. One of the main forms of control of leishmaniasis is chemotherapy, but this is limited by the high cost and/or toxicity of available drugs. We previously found three novel compounds with an iridoid tetracyclic skeleton to have activity against trypanosome parasites. In this study, we determined the activity of the three anti-trypanosome compounds against Leishmania using field strain, 010, and the lab strain Leishmania hertigi. The minimum inhibitory concentration (MIC) of the compounds against 010 was determined by microscopy while the IC50 of compounds against L. hertigi was determined by fluorescence-activated cell sorting with Guava viacount analysis. We found two of the three compounds, molucidin and ML-F52, to have anti-Leishmania activity against both strains. The fluor-microscope observation with DAPI stain revealed that both Molucidin and ML-F52 induced abnormal parasites with two sets of nucleus and kinetoplast in a cell, suggesting that compounds might inhibit cytokinesis in Leishmania parasites. Molucidin and ML-F52 might be good lead compounds for the development of new anti-Leishmania chemotherapy.
doi10.1186/s41182-016-0026-5
pmid27536194
issue1
eissn13494147
oafree_for_read